Scientists have successfully used CRISPR gene editing technology to enhance immune cells within living mice, creating more effective cancer-fighting capabilities. The research represents a significant advance in developing new approaches to cancer immunotherapy by modifying immune cells directly in the body rather than removing them for external modification.
This approach could potentially overcome limitations of current CAR-T cell therapies, which require extracting a patient's immune cells, modifying them in the laboratory, and then reinfusing them. Direct in-vivo editing could make such treatments more accessible and cost-effective while reducing the time between diagnosis and treatment.